CMMB
Chemomab Therapeutics Ltd.
A clinical-stage biotechnology company developing antibody therapies for fibro-inflammatory diseases—conditions that combine inflammation with tissue scarring. Its lead drug, nebokitug, targets a protein called CCL24 to treat liver and skin conditions like primary sclerosing cholangitis. Founded in 2011 by scientist Adi Mor, the company's name blends "chemokine" (its target protein family) with "-mab," the standard suffix for monoclonal antibodies.
ADRUnderlying: CMMBCUSIP: 16385C104HealthcareIL2 holders
Sponsored American Depositary Shares (ADS)
Recent Activity
2022Q2
2 sells
-792 shares
ARK InvestEXIT
-792 shares
-97.5K shares
-97.5K shares
2022Q1
2 sells
-266.5K shares(-99.7%)
ARK InvestTRIM
-266.5K shares(-99.7%)
-206.2K shares(-67.9%)
-206.2K shares(-67.9%)
Loading more activity...